Dallas, Texas 04/16/2014 (FINANCIALSTRENDS) – Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) has reported Internet Short Interest Up 26.1% in March. CHTP has led to research reports by Deutsche Bank. It has also raised the target price from previous $5.00 to $8.00.
The company will remain under Hold rating.
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) has been developing another of the leading product candidate – Droxidopa, will now offer active synthetic precursor which is of the norepinephrine. The company has been developing a range of other clinical development products for pure autonomic failure as well.
Droxidopa is one of the leading synthetic amino acid, which will convert the body which will lead to norepinephrine, will also lead to prodrug which is norephinephrine will lead to replacement therapy, as such as norepinephrine deficiency.
The drug approved and marketed by the organization Dainippon Sumitomo Pharma Co. Ltd, is located in Japan. The stock has led to treat symptomatic orthostatic hypotension. Additionally, it will also help in freezing the PD gait as well as IDH.
Additionally, the company will focus on such development solutions as droxidopa which is in symptomatic NOH. It has also led to prevention of all other falls which are related to PD in NOH.
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) has market capital of $365.50 million. EPS is -0.24. Outstanding shares by this company are in the region of 78.43 million.
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) has also received BUY rating by Roth Capital, with the price target fixed at $7.00. Other analysts too have provided coverage with ‘buy’ rating for One Equities as well.
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) has indicated consensus estimates of $0.07, the average analysts have indicated earnings per share, with post $0.46 earnings.
Additionally, analysts presenting at Needham & Company LLC, which has raised price target to $10.00 from the previous $8.00. The rating is a BUY on this stock.